
Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Else A. Aalbersberg*¹, Daphne M.V. Huizing*¹, Iris Walraven², Berlinda J. de Wit-van der Veen¹, Harshad R. Kulkarni³, Aviral Singh^{3,4}, Marcel P.M. Stokkel¹, and Richard P. Baum^{1,3}

¹Department of Nuclear Medicine, ENETS Centre of Excellence, Netherlands Cancer Institute, Amsterdam, The Netherlands;

²Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; ³Theranostics Centre for Molecular Radiotherapy and Precision Oncology, ENETS Centre of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany; and ⁴GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with neuroendocrine neoplasms. The aim of this study was to identify clinical and treatment parameters associated with progression-free survival (PFS) and overall survival (OS). **Methods:** All patients treated from October 2002 until March 2016 at the Zentralklinik Bad Berka with at least 3 administrations of PRRT (maximal interval of 6 mo between consecutive administrations) were included. Data were collected in 5 categories: general patient characteristics, tumor characteristics, prior treatments, radioisotope used for PRRT, and blood chemistry. Survival was analyzed using Kaplan–Meier curves. Univariate and multivariate Cox regression analyses were performed to identify parameters associated with PFS and OS. **Results:** In total, 782 patients were included, with a median follow-up of 36 mo. The median PFS and OS were 22 and 53 mo, respectively. Parameters associated with lower PFS in the multivariate analysis were a Ki-67 of more than 5%, previous treatment with interferon- α and chemotherapy, presence of diabetes, and chromogranin-A (CgA) levels higher than 336 $\mu\text{g/L}$. Parameters associated with lower OS were a Ki-67 of more than 10%, performance status of at least 1, previous chemotherapy and ablation, and CgA levels higher than 112 $\mu\text{g/L}$. **Conclusion:** Higher Ki-67 values, as well as higher CgA levels and previous chemotherapy, had a negative outcome on both PFS and OS. Furthermore, PFS was negatively associated with previous interferon- α treatment and diabetes, whereas lower OS was related to prior ablation and higher performance status.

Key Words: PRRT; neuroendocrine tumor; multivariate analysis

J Nucl Med 2019; 60:1259–1265

DOI: 10.2967/jnumed.118.224386

Well-differentiated neuroendocrine tumors (NETs) arise from neuroendocrine cells, and although they can occur anywhere throughout the body, the most common locations are the gastrointestinal tract, pancreas, and lungs (1). In the United States, NETs comprise 0.5%

of new cancer diagnoses, with an incidence of approximately 6.98/100,000/y (2). Most NETs are characterized by expression of the somatostatin receptor (SSTR), which can be exploited for diagnostic imaging and radionuclide therapy. Treatment with radiolabeled somatostatin analogs, called peptide receptor radionuclide therapy (PRRT) (3), was introduced using ¹¹¹In-pentetreotide (4), followed by ⁹⁰Y-octreotide and ¹⁷⁷Lu-DOTATATE (5). A randomized phase III PRRT clinical trial (NETTER-1) was concluded in 2017 (6). NETTER-1 applied randomized treatment to NET patients between 4 cycles of ¹⁷⁷Lu-DOTATATE (plus long-acting octreotide acetate, 30 mg/mo) and a control group with high-dose octreotide (long-acting, 60 mg/mo). The progression-free survival (PFS) was 28.4 mo in the ¹⁷⁷Lu-DOTATATE group and 8.4 mo in the control group. On the basis of this trial, PRRT was approved in the United States and Europe for treatment of metastatic or irresectable NETs and is included now in the societal guidelines from the European Neuroendocrine Tumour Society (ENETS), International Atomic Energy Agency, European Association of Nuclear Medicine, and Society of Nuclear Medicine and Molecular Imaging (7,8).

Patient eligibility for PRRT is primarily based on tumor lesion SSTR expression, visualized with ⁶⁸Ga-labeled somatostatin analog PET/CT. Treatment is effective when sufficient uptake is shown on ⁶⁸Ga-somatostatin analog PET/CT (3,9). Several studies have investigated nonimaging parameters that affect outcome after PRRT. Ezziddin et al. demonstrated that a proliferation index (or Ki-67) of less than 20% resulted in good response after PRRT, whereas a Ki-67 of more than 20% often led to progression within 3 mo after treatment (10). Ki-67 was also found to be a predictive factor for overall survival (OS) after PRRT in a multivariate analysis (74 patients). Other factors identified were hepatic tumor burden, performance status, and neuron-specific enolase level (11). Brunner et al. found that SSTR type 2 expression is an independent prognostic marker for OS in 279 NET patients. A subgroup analysis of 61 patients with pancreas NET (pNET) showed that SSTR expression is not a prognostic marker for OS in pNET (12). Other non-histologic parameters associated with survival after PRRT include gene cluster expression (13), primary tumor site (14), resection of the primary tumor (15), dominant liver metastases, and lesion size (14). A previous study to analyze multiple factors was an intention-to-treat analysis and included all patients that started PRRT, but not all received full treatment (16). The aim of the current study was to

Received Dec. 12, 2018; revision accepted Feb. 6, 2019.

For correspondence or reprints contact: Else A. Aalbersberg, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

E-mail: e.aalbersberg@nki.nl

*Contributed equally to this work.

†Contributed equally to this work.

Published online Mar. 8, 2019.

COPYRIGHT © 2019 by the Society of Nuclear Medicine and Molecular Imaging.

identify clinical parameters that predict PFS and OS after PRRT in a large patient population.

MATERIALS AND METHODS

Patients

All patients treated with PRRT at Zentralklinik Bad Berka from October 2002 to March 2016 were reviewed. Patients with histopathologically proven NET were referred for PRRT because of progressive metastatic or inoperable disease. Treatment was performed according to the local Bad Berka protocol (17), followed by the ENETS protocol (7) and the International Atomic Energy Agency/European Association of Nuclear Medicine/Society of Nuclear Medicine and Molecular Imaging protocol (8). SSTR expression was confirmed and dedifferentiation excluded by pretherapy ⁶⁸Ga-somatostatin analog PET/CT and ¹⁸F-FDG PET/CT, respectively, and scored as previously described (18). Renal function was evaluated with ^{99m}Tc-MAG3 renography, and tubular excretion rate was evaluated (8). An in-house-produced amino acid infusion containing lysine and arginine was given during each administration for nephroprotection (17). Patients were treated with ¹⁷⁷Lu, ⁹⁰Y, or both according to the previously described protocol (17). Written informed consent was obtained from all patients before treatment, including data use for research, and institutional review board approval was obtained. The inclusion criteria for this study were at least 3 administrations of PRRT and a maximum of 6 mo between consecutive administrations. Patients previously treated with PRRT at a different center were excluded.

Data Collection

Data were collected in 5 categories: general patient characteristics, tumor characteristics, prior treatments, PRRT radionuclide, and laboratory parameters and tumor biomarkers. Progression was determined on the basis of RECIST or PERCIST criteria (19,20). Progression and survival were determined in January 2017. PFS was calculated from the start of PRRT to progression or death from any cause. OS was calculated from the start of PRRT to death from any cause.

Statistical Analysis

Statistical analyses were performed in SPSS, version 22.0 (IBM). In the case of nonnormal distribution in a histogram, the variable was categorized in quartiles 1, 2, 3, and 4 (Q1, Q2, Q3, and Q4, respectively). Univariate Cox regression was performed to determine the association between single parameters and PFS and OS. In order not to be too stringent, the multivariate Cox regression model included all parameters with a *P* value of less than 0.1 in the univariate analysis. Accordingly, after every iteration the parameter with the highest *P* value (above *P* > 0.05) was removed from the multivariate model (backward selection). The final model contained only variables significantly (*P* < 0.05) associated with survival. In addition, survival per primary tumor location and after primary tumor resection was evaluated.

RESULTS

Patient and PRRT Characteristics

In total, 1,425 patients were reviewed, of whom 782 met the inclusion criteria. The median follow-up time was 36.0 mo (range, 4–155 mo). The mean age before treatment was 60.3 y, and 94.2% of the patients were in good health (World Health Organization [WHO] 0–1). Most tumors (92.4%) were G1/G2. Regarding other treatments, 33.2% of patients were given 1 treatment; 24%, 2 treatments; and 12.9%, 3–5 treatments before PRRT, whereas 29.7% of patients were treatment-naïve. PRRT consisted of 3 administrations (50.4%), 4 administrations (42.1%), or 5–6 administrations (7.5%). Half of the patients were treated with both ¹⁷⁷Lu and ⁹⁰Y

TABLE 1
Patient, Tumor, and Treatment Characteristics

Variable	Characteristic	Data
Sex	Male	444 (56.8%)
	Female	338 (43.2%)
Age (y)		60.3 ± 11.0 (22–83)
Location of primary tumor (n = 782)	Small intestine	221 (28.3%)
	Large intestine	42 (5.4%)
	Lung	60 (7.7%)
	Pancreas	277 (35.4%)
	Unknown primary	106 (13.6%)
	Other	76 (9.7%)
Tumor grade (n = 570)	Grade 1	182 (31.9%)
	Grade 2	345 (60.5%)
	Grade 3	43 (7.5%)
Ki-67 (n = 503)	Q1	≤2%
	Q2	3%–5%
	Q3	6%–10%
	Q4	>10%
Functional tumor (n = 555)	Yes	280 (50.5%)
	No	275 (49.5%)
Performance status (n = 782)	WHO 0	547 (69.9%)
	WHO 1	190 (24.3%)
	WHO 2–3	45 (5.8%)
Comorbidities	Hypertension (n = 239)	99 (41.4%)
	Diabetes (n = 782)	46 (5.9%)
Prior treatment	Interferon-α (n = 727)	36 (5.0%)
	Chemotherapy (n = 727)	159 (21.9%)
	Resection, primary tumor (n = 710)	336 (47.3%)
	Ablation (n = 727)	100 (13.8%)
	Radiotherapy (n = 727)	35 (4.8%)
	Somatostatin analog (n = 727)	297 (40.9%)
Isotope (n = 782)	¹⁷⁷ Lu	295 (37.7%)
	⁹⁰ Y	96 (12.3%)
	¹⁷⁷ Lu and ⁹⁰ Y	391 (50.0%)
PRRT administrations (n = 782)	3	395 (50.4%)
	4	329 (42.1%)
	5–6	59 (7.5%)
	Cumulative activity (GBq) (n = 782)	¹⁷⁷ Lu
	⁹⁰ Y	11.5 (4.8–23.6)
	¹⁷⁷ Lu and ⁹⁰ Y	18.2 (5.0–33.7)
Blood count (n = 782)	Normal	546 (69.8%)
CgA (n = 661)	Q1	<112
	Q2	112–333
	Q3	336–1,168
	Q4	>1,168
Serotonin (n = 627)		273 (10–14,200)
eGFR (n = 778)		81.2 (30.56–259.08)
Creatinine (n = 778)		75.0 (27–186)

Continuous data are mean ± SD followed by range. Categorical data are number followed by percentage. When variables are divided into quartiles, range of quartile is given. Percentages may not add up to 100% due to rounding.

TABLE 2
PFS and OS per Primary Tumor Location

Primary tumor location	PFS (mo)		OS (mo)	
	Median	IQR	Median	IQR
Small intestine	24	17–39	67	36–111
Large intestine	22	14–33	51*	24–68
Lung	18†	14–26	41*	30–67
Pancreas	23	16–35	50*	28–88
Cancer of unknown primary	23	17–35	59	36–104
Other	19	14–31	52	96–22
Overall	22	16–35	53	30–98

*Significant in univariate analysis.

(Supplemental Table 1; supplemental materials are available at <http://jnm.snmjournals.org>), whereas 37.7% received ^{177}Lu only and 12.3% ^{90}Y only. Most patients had NETs originating from the small intestine (28.3%) or pancreas (35.4%), and 50% of the patients had a functional tumor. All patient characteristics are shown in Table 1. Table 2 presents the PFS and OS per primary tumor location, showing that gastroenteropancreatic NETs have a higher PFS and OS.

PFS

Progression was observed in 643 patients (82.2%), with a median PFS of 22 mo (interquartile range [IQR], 14.0–31.3; Fig. 1A). In univariate analyses, 10 parameters were associated with lower PFS: primary tumor in the lung compared with primary tumor in the small intestine (hazard ratio [HR], 1.625; confidence interval [CI], 1.186–2.226), performance status (WHO 1 [HR, 1.352; CI, 1.127–1.623] and WHO 2/3 [HR, 1.741; CI, 1.262–2.402] compared with WHO 0), and prior treatments with chemotherapy (HR, 1.362; CI, 1.123–1.652), interferon- α (HR, 1.487; CI, 1.046–2.114), and radiotherapy (HR, 2.059; CI, 1.420–2.984). Furthermore, Ki-67 for Q3 (Ki-67 = 5%–10% [HR, 1.466; CI, 1.111–1.934]), and Q4 (Ki-67 > 10% [HR, 1.631; CI, 1.230–2.163]), resulted in lower PFS than Ki-67 for Q1 (Ki-67 < 2%). Finally, initial chromogranin-A (CgA) levels for Q3 (CgA = 336–1,168 $\mu\text{g/L}$ [HR, 1.580; CI, 1.241–2.011]) and Q4 (CgA > 1,168 $\mu\text{g/L}$ [HR, 2.148; CI, 1.679–2.747]) were associated with lower PFS than CgA for Q1 (CgA < 112 $\mu\text{g/L}$). Only the combination of ^{177}Lu and ^{90}Y was positively associated with PFS compared with ^{177}Lu alone (HR,

0.797; CI, 0.672–0.944). Different treatment strategies concerning the isotopes resulted in median PFS of 20 mo for ^{177}Lu , 25 mo for ^{90}Y , and 23 mo for treatment with both isotopes. Finally, G3 tumors showed lower PFS than G1 (HR, 1.522; CI, 1.062–2.180), with a median of 23 mo for G1, 21 mo for G2, and 18 mo for G3.

The final multivariate model included Ki-67 for Q3 (HR, 1.419; CI, 1.041–1.935) and Q4 (HR, 1.493; CI, 1.090–2.045), compared with Q1, prior treatment with chemotherapy (HR, 1.375; CI, 1.039–1.820), interferon- α (HR, 2.054; CI, 1.211–3.485), presence of diabetes (HR, 1.706; CI, 1.117–2.605), and CgA for Q3 (HR, 1.469; CI, 1.084–1.992) and Q4 (HR, 2.039; CI, 1.488–2.794). All significant results regarding PFS are shown in Table 3, and the full results are in Supplemental Table 2.

OS

Median OS was 53 mo (IQR, 18.0–57.0), and death from any cause was observed in 405 patients (51.8%) (Fig. 1B). Eleven parameters were associated with lower OS in univariate analyses: primary tumor in the pancreas (HR, 1.519; CI, 1.184–1.948), large intestine (HR, 1.594; CI, 1.003–2.533), and lung (HR, 1.716; CI, 1.150–2.560) compared with the small intestine; performance status (WHO 1 [HR, 1.781; CI, 1.432–2.214] and WHO 2/3 [HR, 2.817; CI, 1.941–4.089] compared with WHO 0); and prior treatment with ablation (HR, 1.458; CI, 1.103–1.928), interferon- α (HR, 1.504; CI, 1.002–2.256), radiotherapy (HR, 1.780; CI, 1.120–2.829), and chemotherapy (HR, 1.792; CI, 1.434–2.239). Ki-67 for Q3 (HR, 1.519; CI, 1.051–2.194) and Q4 (HR, 2.143; CI, 1.488–3.087) resulted in lower PFS than Ki-67 for Q1. Furthermore, initial CgA levels for Q2 (112–336 $\mu\text{g/L}$ [HR, 1.531; CI, 1.100–2.131]), Q3 (HR, 1.887; CI, 1.354–2.631) and Q4 (HR, 3.357; CI, 2.434–4.631) were associated with lower PFS than CgA for Q1. Both resection of the primary tumor (HR, 0.715; CI, 0.584–0.877) and the combination of ^{177}Lu and ^{90}Y compared with ^{177}Lu alone (HR, 0.792; CI, 0.636–0.986) were associated with improved OS. The median OS was 48 mo for patients treated with only ^{177}Lu , 57 mo for patients treated with only ^{90}Y , and 56 mo for patients treated with both isotopes. Finally, G2 tumors (HR, 1.394; CI, 1.065–1.826) and G3 tumors (HR, 2.473; CI, 1.621–3.772) showed lower OS than G1 tumors, with a median of 74 mo for grade 1, 51 mo for grade 2, and 26 mo for grade 3. For selected results, Kaplan–Meier curves are shown in Figures 2 and 3.

In the multivariate analysis, the following parameters were associated with lower OS: Ki-67 for Q4 (HR, 1.930; CI, 1.285–2.899) compared with Q1, performance status (WHO 1 [HR, 1.551; CI, 1.109–2.169] and WHO 2/3 [HR, 2.305; CI, 1.432–3.713] compared with WHO 0), ablation (HR, 1.519; CI, 1.041–2.215), chemotherapy (HR, 1.979; CI, 1.412–2.773), and CgA for Q2 (HR, 1.690; CI, 1.095–2.608), Q3 (HR, 1.816; CI, 1.718–2.799), and Q4 (HR, 2.671; CI, 1.717–4.155) compared with CgA for Q1. The median OS was 47 mo (IQR, 29–80) without and 64 mo (IQR, 32–112) with resection of the primary tumor, significantly different in primary pancreas or small-intestine NETs after univariate Cox regression analysis (Table 4). All results with regard to OS are shown in Table 5 and Supplemental Table 3.

DISCUSSION

The reported PFS in other studies (32–41 mo) is higher than in the current study




FIGURE 1. Kaplan–Meier curves of PFS (A) and OS (B).




FIGURE 2. Kaplan–Meier curves of OS after resection of primary tumor and OS per primary tumor location. Median OS is 43 and 65 mo without and with resection, respectively. Median OS is 67 mo for small-intestine NETs, 51 mo for large intestine, 41 mo for lung, 50 mo for pancreas, 59 mo for cancer of unknown primary (CUP), and 52 mo for other NETs.

(22 mo). Meanwhile, the OS (43 mo) of the current patient cohort was within the reported range in the literature (38–82 mo) (21–26). However, differences between the current study and the literature exist. One study reported higher PFS and OS, yet only gastroenteropancreatic NET patients were included (22). These patients are known to have a better survival than patients with primary lung and colon NETs (27). Another study included only patients with G1/G2 tumors, who are likely to have a longer OS than patients with G3 tumors (24). In our study, high-risk patients with characteristics such as G3 tumors, WHO 2/3, and nongastroenteropancreatic NETs were also included.

Tumor grade was significantly associated in the univariate analysis with both PFS and OS. Differences in survival between G1 and G2 tumors were previously shown (28); however, this study observed differences only in the univariate analysis. Because tumor grade and Ki-67 index are related (29), both indicate a more aggressive tumor, whereas the latter is generally associated with shorter OS (30). Ezziddin et al. showed in 74 patients that patients with a Ki-67 of more than 10% have both lower PFS and lower OS (11). In the current study, this finding was confirmed from a Ki-67 of more than 5% for PFS and more than 10% for OS in multivariate analysis. The performance status is a well-known factor that affects PFS and OS regardless of tumor type. The current study found that patients with WHO 1 and WHO 2/3 have decreased OS compared with patients with WHO 0, a result that was also confirmed by another study (25).

Our data showed a reduction in PFS and OS in both univariate and multivariate analysis in patients pretreated with chemotherapy, as was also demonstrated in other studies (23,25). Additional analysis in our dataset revealed that of the 43 patients with a G3 tumor, 19 (44%) were treated with chemotherapy, whereas among patients with G1 and G2 tumors, only 12% and 23%, respectively, were treated with chemotherapy. According to current ENETS guidelines, chemotherapy is indicated for G3 neuroendocrine neoplasms (31). Therefore, the association between chemotherapy and survival might be the result of high-grade tumor patients receiving chemotherapy.

Resection of the primary tumor significantly improved OS (47 vs. 64 mo), significantly different in primary pNETs or small intestine NETs after univariate Cox regression analysis (Table 4). Bertani et al. reported an OS of 112 mo without resection and 65 mo with resection, and resection increased the median PFS (70 vs. 30 mo). The longer OS reported could be explained by solely including G1/G2 pNET patients with liver metastases only (15). Prolonged OS after resection of the primary tumor was also observed in pNET populations in a systematic review and metaanalysis (32). According to current guidelines, resection of the primary tumor is indicated for G1/G2 tumors with curative intent, and the presence of liver or lymph node metastases is not a contraindication for primary tumor resection (31). Resection of a primary pNET is hypothesized to improve survival because of underlying anatomic and biologic mechanisms. First, part of the pancreatic venous blood flow drains into the portal vein, which directly flows into liver parenchyma, which is therefore the first organ reached by metastatic pNET cells (seed-and-soil hypothesis). Second, the liver might be more susceptible to metastases because of its microenvironment with stromal build-up, growth factors, and immune cells (metastatic niche hypothesis) (33,34). Thus, resection of the primary tumor, as the source of metastasizing cells, may improve survival even in the presence of metastases.

High levels of the biomarker CgA were associated with lower PFS and OS in the current patient population. CgA levels greater than 336 $\mu\text{g/L}$ before PRRT were predictors for lower PFS, where for OS this level was greater than 112 $\mu\text{g/L}$. Previous studies showed




FIGURE 3. Kaplan–Meier curves of OS per Ki-67 and CgA quartiles and performance status classes. Median OS is 74 mo for Ki-67 < 2%, 54 mo for 2%–5%, 56 mo for 5%–10%, and 32 mo for >10%. Median OS is 86 mo for CgA < 112, 61 mo for 112–336, 54 mo for 336–1,168, and 35 mo for >1,168. Median OS is 64 mo for WHO 0, 41 mo for WHO 1, and 37 mo for WHO 2/3.

TABLE 3
PFS Analysis

Parameter	Group	Univariate			Multivariate		
		HR	95% CI	P	HR	95% CI	P
Ki-67	Q1: <2%	1		0.002	1		0.044
	Q2: 2%–5%	1.165	0.898–1.513		1.171	0.880–1.557	
	Q3: 5%–10%	1.466	1.111–1.934		1.419	1.041–1.935	
	Q4: >10%	1.631	1.230–2.163		1.493	1.090–2.045	
Comorbidities	Diabetes	1.373	0.989–1.907	0.058 [†]	1.706	1.117–2.605	0.013
Prior treatment	Chemotherapy	1.362	1.123–1.652	0.002 [†]	1.375	1.039–1.820	0.026
	Interferon- α	1.487	1.046–2.114	0.027	2.054	1.211–3.485	0.008
CgA ($\mu\text{g/L}$)	Q1: <112	1		<0.001	1		<0.001
	Q2: 112–333	1.189	0.932–1.517		1.267	0.922–1.741	
	Q3: 336–1,168	1.580	1.241–2.011		1.469	1.084–1.992	
	Q4: >1,168	2.148	1.679–2.747		2.039	1.488–2.794	

HR > 1 indicates greater risk for disease progression compared with reference value (HR = 1).

that CgA levels greater than 600 $\mu\text{g/L}$ were associated with shorter PFS and OS in smaller patient populations (35,36). The current ENETS guidelines indicate that high CgA levels indicate poorer prognosis, probably associated with a high tumor load (29,37).

In the current study, the choice of the radioisotope did not influence PFS and OS in the multivariate analysis. In the univariate analysis, however, the combination of ^{177}Lu and ^{90}Y improved OS and PFS compared with ^{177}Lu alone. This result is different from the results of a German cohort study, in which treatment with only ^{90}Y was associated with decreased OS compared ^{177}Lu only or tandem PRRT (^{177}Lu and ^{90}Y concurrently) (21). Nevertheless, it is known that ^{90}Y implies a risk for nephrotoxicity compared with ^{177}Lu alone (38). However, a bias in radionuclide selection exists in the current study because patients with a large tumor burden often receive tandem PRRT (17).

Besides the disadvantages inherent in a retrospective analysis, this study had other limitations. First, information about the extent of the disease (tumor burden and hepatic involvement) was not included, because the goal was to define non-imaging-

related parameters. Second, patients could have received other treatments after PRRT, which could have extended their survival, but this aspect was beyond the scope of this research. Also, toxicity was not covered in this study but has been evaluated in another large multivariate analysis (38). Nephrologic disease could decrease life expectancy, yet nephrotoxicity and related side effects due to medical interventions were not taken into consideration as confounders for survival in this study.

The association of some parameters in this dataset with PFS and OS has already been described in other papers (12,23,25,28–30,32,35,36). However, to our knowledge, this is the first study that combines all parameters in a multivariate analysis. The fact that some patients have factors that are related to shorter PFS or OS does not indicate that PRRT is an unsuitable treatment for these patients. Patients could still respond to treatment and have a longer PFS or OS compared with other treatments. This is especially true for patient with G3 tumors or SSTR-positive neuroendocrine carcinomas (39). Furthermore, this study might help physicians and patients manage expectations from PRRT based on individual characteristics.

TABLE 4
Resection of Primary per Tumor Location

Location of primary	Median OS (mo)		Univariate Cox regression analysis		
	Resected	Unresected	HR	95% CI	P
Small intestine	77 (37–134)	48 (32–90)	0.649	0.423–0.995	0.047*
Large intestine	51 (28– ∞)	45 (24–61)	0.625	0.257–1.522	0.301
Lung	51 (26–67)	41 (31–45)	0.755	0.374–1.522	0.432
Pancreas	65 (35–112)	43 (24–69)	0.595	0.426–0.832	0.002*
Overall	64 (32–112)	47 (29–80)	0.715	0.584–0.877	0.001*

*Significant.

Data in parentheses are IQR.

TABLE 5
OS Analysis

Parameter	Group	Univariate			Multivariate		
		HR	95% CI	P	HR	95% CI	P
Ki-67	Q1: <2%	1		0.001	1		0.014
	Q2: 2%–5%	1.340	0.960–1.871		1.363	0.946–1.965	
	Q3: 5%–10%	1.519	1.051–2.194		1.203	0.798–1.814	
	Q4: >10%	2.143	1.488–3.087		1.930	1.285–2.899	
Performance status	WHO 0	1		<0.001	1		0.010
	WHO 1	1.781	1.432–2.214		1.551	1.109–2.169	
	WHO 2–3	2.817	1.941–4.089		2.305	1.432–3.713	
Prior treatment	Ablation	1.458	1.103–1.928	0.008	1.519	1.041–2.215	0.030
	Chemotherapy	1.792	1.434–2.239	<0.001	1.979	1.412–2.773	<0.001
CgA (µg/L)	Q1: <112	1		<0.001	1		<0.001
	Q2: 112–336	1.531	1.100–2.131		1.690	1.095–2.608	
	Q3: 336–1,168	1.887	1.354–2.631		1.816	1.718–2.799	
	Q4: >1,168	3.357	2.434–4.631		2.671	1.717–4.155	

HR > 1 indicates greater risk for death of any cause and HR < 1 lower risk.

CONCLUSION

Higher Ki-67 values, as well as higher CgA levels and previous chemotherapy, had a negative outcome on both PFS and OS. Furthermore, PFS was negatively associated with previous interferon- α treatment and diabetes, whereas lower OS was related to prior ablation and higher performance status.

DISCLOSURE

Richard Baum received honoraria from Ipsen Pharma, ROTOP Pharmaka, OctreoPharm Sciences GmbH, and Advanced Accelerator Applications outside the submitted work. No other potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENT

We thank Karin Niepsch for her support in data collection.

KEY POINTS

QUESTION: Can clinical and treatment parameters be associated with progression-free survival (PFS) and overall survival (OS) after peptide receptor radionuclide therapy (PRRT)?

PERTINENT FINDINGS: Patients ($n = 782$) treated with at least 3 cycles of PRRT were retrospectively reviewed, data were collected in 5 categories (general patient characteristics, tumor characteristics, prior treatments, radioisotope used for PRRT, blood chemistry), and univariate and multivariate Cox regression analyses were performed. Higher Ki-67 values, higher chromogranin-A levels, and previous chemotherapy had a negative outcome on both PFS and OS; lower PFS was associated with previous interferon- α treatment and diabetes; and lower OS was related to prior ablation and higher performance status.

IMPLICATIONS FOR PATIENT CARE: Knowledge of parameters associated with PFS and OS after PRRT can guide both physicians and patients in their choice for PRRT.

REFERENCES

- Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. *Cancer Metastasis Rev*. 2011;30(suppl 1):3–7.
- Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. *Neoplasia*. 2017;19:991–1002.
- Cives M, Strosberg J. Radionuclide therapy for neuroendocrine tumors. *Curr Oncol Rep*. 2017;19:9.
- Krenning EP, Kooij P, Bakker W, et al. Radiotherapy with a radiolabeled somatostatin analogue, [¹¹¹In-DTPA-D-Phe¹]-octreotide: a case history. *Ann N Y Acad Sci*. 1994;733:496–506.
- Bodei L, Kidd M, Baum RP, Modlin IM. PRRT: defining the paradigm shift to achieve standardization and individualization. *J Nucl Med*. 2014;55:1753–1756.
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. *N Engl J Med*. 2017;376:125–135.
- Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. *Neuroendocrinology*. 2009;90:220–226.
- Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2013;40:800–816.
- Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. *Future Oncol*. 2014;10:2259–2277.
- Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. *Eur J Nucl Med Mol Imaging*. 2011;38:459–466.
- Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate. *J Nucl Med*. 2014;55:183–190.
- Brunner P, Jörg AC, Glatz K, et al. The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2017;44:468–475.
- Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2016;43:839–851.
- Kong G, Thompson M, Collins M, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). *Eur J Nucl Med Mol Imaging*. 2014;41:1831–1844.

15. Bertani E, Fazio N, Radice D, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1–G2 pancreatic neuroendocrine tumors with unresectable liver metastases. *Ann Surg Oncol*. 2016;23:981–989.
16. Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with ⁹⁰yttrium and ¹⁷⁷lutetium in 1048 patients with neuroendocrine neoplasms. *Oncotarget*. 2018;9:16932–16950.
17. Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka experience. *Theranostics*. 2012;2:437–447.
18. Chan DL, Pavlakis N, Schembri GP, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. *Theranostics*. 2017;7:1149–1158.
19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009;50(suppl):122S–150S.
20. Eisenhauer EA, Therasse P, Bogaers J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45:228–247.
21. Hörsch D, Ezziddin S, Haug A, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. *Eur J Cancer*. 2016;58:41–51.
22. Brabander T, Van Der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. *Clin Cancer Res*. 2017;23:4617–4624.
23. Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. *Eur J Nucl Med Mol Imaging*. 2016;43:441–452.
24. Kunikowska J, Pawlak D, Bąk MI, Kos-Kudła B, Mikołajczak R, Królicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with ⁹⁰Y/¹⁷⁷Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. *Ann Nucl Med*. 2017;31:347–356.
25. Katona BW, Roccaro GA, Soulen MC, et al. Efficacy of peptide receptor radionuclide therapy in a United States–based cohort of metastatic neuroendocrine tumor patients. *Pancreas*. 2017;46:1121–1126.
26. Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. *Eur J Nucl Med Mol Imaging*. 2018;45:970–988.
27. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol*. 2017;3:1335–1342.
28. Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2014;41:925–933.
29. Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. *Neuroendocrinology*. 2016;103:125–138.
30. Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. *Br J Cancer*. 2013;108:1838–1845.
31. Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. *Neuroendocrinology*. 2016;103:172–185.
32. Zhou B, Zhan C, Ding Y, Yan S, Zheng S. Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. *Onco Targets Ther*. 2018;11:975–982.
33. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer*. 2009;9:285–293.
34. Hann A, Sainz B Jr, Hermann PC. The metastatic niche in the liver: tilling the soil for pancreatic cancer progression. *Transl Cancer Res*. 2017;6(suppl):S217–S220.
35. Sabet A, Haug AR, Eiden C, et al. Efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. *Am J Nucl Med Mol Imaging*. 2017;7:74–83.
36. Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-octreotate in advanced neuroendocrine tumours of the small intestine. *Eur J Nucl Med Mol Imaging*. 2015;42:1238–1246.
37. Korse CM, Bonfrer JMG, Aaronson NK, Hart AAM, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. *Neuroendocrinology*. 2009;89:296–301.
38. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging*. 2015;42:5–19.
39. Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN): a single-institution retrospective analysis. *Eur J Nucl Med Mol Imaging*. 2018;45:262–277.